EUVIMEDEUVIMED entdecken
Klinische StudieMultizentrische Studie

Five-Year Outcomes for Patients With RVOT Dysfunction Treated With the SAPIEN 3 Transcatheter Heart Valve: A Pooled Analysis From the COMPASSION S3 Trial

Michael R Hainstock, Gregory Fleming iD, Dennis Kim, Jamil Aboulhosn iD, Daniel Levi iD, Richard Krasuski iD, Robert Sommer iD, Alejandro J Torres iD, Robert Gray, Dean Kereiakes iD, Andrew Leventhal, Matthew Gillespie und 13 weitere

Circulation: Cardiovascular Interventions · 2026

DOI: 10.1161/circinterventions.125.016361 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Circulation: Cardiovascular Interventions, 2026. Verfasst von Michael R Hainstock und 24 weiteren Autor:innen. Beteiligte Einrichtung: University of Virginia, Charlottesville (M.R.H., D.S.L.). Hauptthemen laut MEDLINE: Cardiac Catheterization, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation, Pulmonary Valve. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The COMPASSION S3 trial (Congenital Multicenter Trial of Pulmonic Valve Dysfunction Studying the SAPIEN 3 Interventional Transcatheter Heart Valve) was designed to evaluate the safety and effectiveness of the SAPIEN 3 transcatheter heart valve (THV) for transcatheter pulmonic valve replacement in patients with a dysfunctional right ventricular outflow tract (RVOT) conduit or previously implanted valve in the pulmonic position. Here, 5-year clinical and hemodynamic outcomes for patients in the main cohort and the continued access protocol are reported. METHODS: The COMPASSION S3 trial was a single-arm, multicenter study enrolling patients with either moderate-to-severe pulmonic regurgitation, a mean RVOT gradient ≥35 mm Hg, or both. The primary end point was THV dysfunction at 1 year, a nonhierarchical composite of RVOT reintervention, ≥moderate total pulmonic regurgitation, and mean RVOT gradient >40 mm Hg. Clinical and echocardiographic outcomes were assessed at baseline, discharge, 30 days, 6 months, 1 year, and then annually to 5 years. RESULTS: Between 2016 and 2020, 69 patients were enrolled and successfully implanted with the SAPIEN 3 THV. The mean patient age was 32.1 years, and most patients (70.8%) had a conduit as the most recent prior intervention. At 5 years, the rate of THV dysfunction was 12.0%: 3 patients required reintervention, 2 patients had ≥moderate pulmonic regurgitation, and 1 patient had a mean gradient >40 mm Hg. There were 3 cases of device-related endocarditis (4.4%). One death occurred on postoperative day 560 due to cardiogenic shock. No cases of tricuspid valve injury, stent fractures, or valve malposition were reported. Post-transcatheter pulmonic valve replacement, mean gradients were low and stable through 5-year follow-up. Through 5 years, >95% of patients had ≤mild total pulmonic regurgitation, and 97.9% of patients had none/trace paravalvular regurgitation. CONCLUSIONS: Five-year results from the COMPASSION S3 trial demonstrate that the SAPIEN 3 THV provides durable RVOT relief with low rates of reintervention or endocarditis, supporting the device as a safe and versatile option for transcatheter pulmonic valve replacement across diverse anatomies and clinical scenarios. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02744677.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiac CatheterizationHeart Valve ProsthesisHeart Valve Prosthesis ImplantationPulmonary ValvePulmonary Valve InsufficiencyVentricular Function, RightAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultCompassionate Use TrialsHemodynamicsProsthesis DesignRecovery of FunctionRisk FactorsTime FactorsTreatment OutcomeVentricular Outflow Obstruction, Right

Stichwörter der Autor:innen

endocarditishemodynamicspulmonary valve insufficiencypulmonary valve stenosisstents

Autor:innen und Institutionen

  • University of Virginia, Charlottesville (M.R.H., D.S.L.).
  • Duke University Medical Center, Durham, NC (G.F., R.K.).
  • Emory University, Atlanta, GA (D. Kim, V.B.).
  • University of California, Los Angeles (J.A., D.L.).
  • Columbia University Irving Medical Center, New York, NY (R.S., A.J.T.).
  • University of Utah at Primary Children's Hospital, Salt Lake City (R.G.).

ORCID-Profile: Gregory Fleming, Jamil Aboulhosn, Daniel Levi, Richard Krasuski, Robert Sommer, Alejandro J Torres, Dean Kereiakes, Alan Zajarias, Shabana Shahanavaz, Zachary L Steinberg, Thomas K Jones, Vaikom S Mahadevan, Sammy Elmariah, Vasilis Babaliaros, D Scott Lim

Zitieren

APA

Hainstock, M. R., Fleming, G., Kim, D., Aboulhosn, J., Levi, D., Krasuski, R., Sommer, R., Torres, A. J., Gray, R., Kereiakes, D., Leventhal, A., Gillespie, M., Szeto, W., Zajarias, A., Shahanavaz, S., Steinberg, Z. L., Jones, T. K., Mahadevan, V. S., Moore, P., …, & COMPASSION 3 Trial Executive Committee and Study Investigators (2026). Five-Year Outcomes for Patients With RVOT Dysfunction Treated With the SAPIEN 3 Transcatheter Heart Valve: A Pooled Analysis From the COMPASSION S3 Trial. Circulation: Cardiovascular Interventions. https://doi.org/10.1161/circinterventions.125.016361

Vancouver

Hainstock MR, Fleming G, Kim D, Aboulhosn J, Levi D, Krasuski R, et al. Five-Year Outcomes for Patients With RVOT Dysfunction Treated With the SAPIEN 3 Transcatheter Heart Valve: A Pooled Analysis From the COMPASSION S3 Trial. Circulation: Cardiovascular Interventions. 2026. doi:10.1161/circinterventions.125.016361

BibTeX
@article{Hainstock2026,
  author = {Hainstock, Michael R and Fleming, Gregory and Kim, Dennis and Aboulhosn, Jamil and Levi, Daniel and Krasuski, Richard and Sommer, Robert and Torres, Alejandro J and Gray, Robert and Kereiakes, Dean and Leventhal, Andrew and Gillespie, Matthew and Szeto, Wilson and Zajarias, Alan and Shahanavaz, Shabana and Steinberg, Zachary L and Jones, Thomas K and Mahadevan, Vaikom S and Moore, Phillip and Elmariah, Sammy and Shirali, Girish and Li, Wenhao and Babaliaros, Vasilis and Lim, D Scott and COMPASSION 3 Trial Executive Committee and Study Investigators, COMPASSION 3 Trial Executive Committee and Study Investigators},
  title = {Five-Year Outcomes for Patients With RVOT Dysfunction Treated With the SAPIEN 3 Transcatheter Heart Valve: A Pooled Analysis From the COMPASSION S3 Trial},
  journal = {Circulation: Cardiovascular Interventions},
  year = {2026},
  doi = {10.1161/circinterventions.125.016361}
}
Kostenlos starten →